Ocular Drug Delivery Devices Market Share

  • Report ID: 4029
  • Published Date: Dec 20, 2024
  • Report Format: PDF, PPT

Ocular Drug Delivery Devices Industry - Regional Synopsis

North American Market Forecast

North America industry is poised to dominate majority revenue share by 2037. The growth of the market can be attributed majorly to growing cases of ocular diseases in underdeveloped countries. As per a WHO report, the instances of distance vision impairment in low-income regions are estimated to be four times higher than in high-income regions, and near vision impairment is estimated to be 80% more in western, eastern, and central sub-Saharan Africa. The rising pharmaceutical sector and increasing research and development to improve the drug delivery system of diseases are estimated to hike the market growth. The growing number of collaborations and increasing market players in the region also propel the market growth.

The market in the North American region is anticipated to gain the largest market share throughout the forecast period owing to the growing cases of cataracts and diabetes-related visual conditions in the region. An estimated 20.5 million (17.2%) Americans aged above 40 years have a cataract in one or both eyes, according to statistics by the Centers for Disease Control and Prevention (CDC).

Ocular Drug Delivery Devices Market share

Browse key industry insights with market data tables & charts from the report:

Frequently Asked Questions (FAQ)

In the year 2025, the industry size of ocular drug delivery devices is estimated at USD 17.82 billion.

The ocular drug delivery devices market size was valued at USD 15.69 billion in 2024 and is set to exceed USD 43.71 billion by 2037, expanding at over 8.2% CAGR during the forecast period i.e., between 2025-2037. Increasing prevalence of ocular diseases and growing awareness amongst people regarding vision impairment will fuel the market growth.

North America industry is poised to dominate majority revenue share by 2037, owing to growing cases of cataracts and diabetes-related visual conditions in the region.

The major players in the market are Bausch Health Companies Inc., Taiwan Liposome Company, Ltd., Ocular Therapeutix, Inc., Kiora Pharmaceuticals, Inc., Graybug Vision Inc., Apellis Pharmaceuticals, Inc., Implanet Company, Aerie Pharmaceuticals Inc., EyePoint Pharmaceuticals, Inc., Protalix BioTherapeutics
Inquiry Before Buying Request Free Sample PDF
footer-bottom-logos